Background and Objectives: Adult-onset Still’s disease (AOSD) is a rheumatic disease characterized by systemic inflammatory symptoms, including intermittent spiking fever, polyarthritis and a distinctive salmon-colored rash. Corticosteroids are the first-line treatment for AOSD. However, corticosteroids are potentially hepatotoxic in certain cases and may complicate the course of the disease. Materials and Methods: A 29-year-old female suffering from fever of unknown origin for two weeks was diagnosed with AOSD according to Yamaguchi’s criteria. She received corticosteroids as the first-line treatment for AOSD and developed acute severe hepatitis. A diagnostic protocol has been performed. Results: Corticosteroid-induced liver injury was confirmed by clinical observation and rechallenge of the drug in this case. The result of liver biopsy also supported the diagnosis. Mycophenolic acid, a disease-modifying antirheumatic drug (DMARD) was chosen as an alternative treatment. AOSD remission was achieved under this treatment after three months. Conclusions: Severe acute hepatitis induced by corticosteroids, although very rare, may be observed in patients with AOSD. Drug-induced liver injury needs to be kept in mind when unexpected acute hepatitis is found. Mycophenolic acid could be a proper substitute medication in these cases.
Rheumatoid arthritis (RA) is the most common autoimmune rheumatic disease in Taiwan. Anti-cyclic citrullinated peptide (anti-CCP) assay is widely used for RA diagnosis; however, not all anti-CCPs are detectable in RA-joint lesions. Citrullinated α-enolase peptide (CEP), which has a unique immunodominant epitope, can be detected in synovial fluid. Here, we aimed to evaluate the potential of anti-CEP as a serologic marker for the early diagnosis of RA and a prognostic predictor of joint destruction. We also determined the association of single-nucleotide polymorphisms (SNPs) in genes with the serological status and clinical characteristics of RA. Clinical records of 30 patients with RA were collected, and their serum and DNA samples were evaluated using enzyme-linked immunosorbent assay (ELISA) and SNP cross-reaction analysis. A considerable amount of anti-CEP was detected in patients with RA, a trend similar to that of anti-CCP. Moreover, anti-CEP was considerably associated with the protein-arginine deiminase type-2 SNP rs1005753.
11 October 2025 in Journal of Translational Autoimmunity
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by immune dysregulation affecting multiple organs, most notably lupus nephritis (LN). Genetic susceptibility significantly contributes to disease severity and prognosis. However, genomic studies specific to Taiwanese SLE patients, particularly those focusing on LN, remain limited. This study aimed to identify genetic variants associated with SLE and LN in a Taiwanese cohort. Genome-wide association studies (GWAS) were performed on 276 Taiwanese SLE patients compared with 3393 patients with other rheumatic diseases. Single-nucleotide polymorphism (SNP) genotyping was conducted using the Taiwan Precision Medicine Array, with analyses adjusted for age, sex, and population structure. Functional annotations and biomarkers of renal function were assessed for identified SNPs. Compared with patients with other rheumatic diseases, a novel protective variant, rs9480438 (ARID1B), was identified in the SLE group, suggesting an association with dysregulation of cell cycle checkpoints. In the LN group, a protective variant, rs1294028 (SPSB1), and a risk variant, rs17079029 (RAET1-G/RAET1-AS), were linked to altered serum biomarkers and potential pathogenesis influenced by TGFβ and NK cells. Novel genetic variants related to immune regulation and autoimmunity in Taiwanese SLE and LN patients were identified. These variants provide insight into disease mechanisms and may guide early detection and personalized therapeutic approaches.
Pulmonary arterial hypertension (PAH) is a lethal condition marked by the proliferation and remodeling of small pulmonary arteries, ultimately leading to right ventricular hypertrophy and right heart failure. PAH secondary to connective tissue diseases (CTDs) is a progressive complication with a complex pathogenesis that results in the reduced efficacy of vasodilation-based therapies and poor clinical outcomes. Systemic sclerosis is the most commonly associated CTD with PAH in Western countries and has been most extensively investigated. Systemic lupus erythematosus and other CTDs may also be associated with PAH; however, they are less studied. In this review, we explore the general pathobiology of PAH, with a particular emphasis on recent advances in the molecular pathogenesis of CTD-PAH, including endothelial cell dysfunction, dysregulated cell proliferation and vascular remodeling, extracellular matrix remodeling, in situ thrombosis, right ventricular dysfunction, genetic aberrations, and immune dysregulation. We also conduct a thorough investigation into the potential serum biomarkers and immune dysregulation associated with CTD-PAH, summarizing the associated autoantibodies, cytokines, and chemokines. Furthermore, relevant animal models that may help unravel the pathogenesis and contribute to the development of new treatments are also reviewed.
15 February 2023 in International Journal of Rheumatic Diseases